Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) FCF Margin (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed FCF Margin for 7 consecutive years, with 21695.8% as the latest value for Q2 2022.

  • On a quarterly basis, FCF Margin rose 956740984.0% to 21695.8% in Q2 2022 year-over-year; TTM through Mar 2023 was 59216.09%, a 447015.0% decrease, with the full-year FY2025 number at 659.75%, changed N/A from a year prior.
  • FCF Margin was 21695.8% for Q2 2022 at Crescent Biopharma, up from 72675.25% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 38.98% in Q1 2020 to a low of 9589105.63% in Q2 2021.
  • A 3-year average of 1213944.61% and a median of 12775.32% in 2020 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -6670709bps in 2021, then soared 956740984bps in 2022.
  • Crescent Biopharma's FCF Margin stood at 5968.15% in 2020, then plummeted by -1118bps to 72675.25% in 2021, then skyrocketed by 70bps to 21695.8% in 2022.
  • Per Business Quant, the three most recent readings for CBIO's FCF Margin are 21695.8% (Q2 2022), 72675.25% (Q4 2021), and 19582.49% (Q3 2021).